Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Vadim Koshkin MD

Vadim S. Koshkin MD

Assistant Professor, University of California, San Francisco, California

Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco with interests in clinical and translational research. He completed his medical school at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and oncology fellowship at the Cleveland Clinic. He started as faculty at the University of California San Francisco (UCSF) in 2018, focusing on the care of patients with genitourinary malignancies and on building the bladder cancer program. His research interests have focused on clinical trials, targeted agents and biomarkers in bladder cancer, as well as radioligand therapies and imaging in bladder and prostate cancer. He is co-leading the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, a large, multi-institutional, retrospective study of patients with advanced urothelial cancer treated with novel ADCs and targeted agents. At UCSF he serves as the site committee co-chair of the Molecular Imaging & Radionuclide Therapy site committee. Dr. Koshkin is the author of numerous manuscripts and book chapters including first author publications in JCO, Clinical Cancer Research, Cancer and JITC, and has presented his research at numerous national meetings.

Disclosures

Dr. Koshkin has served in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seagen, Astellas, Dendreon, Guidepoint, GLG and ExpertConnect; has received research funding for the institution from Endocyte, Nektar, Clovis, Janssen and Taiho and is supported by the Prostate Cancer Foundation.